SERPINA1 and Gaucher disease: The next step involved in the implementation approach of the framework in the drug review process was appraising three orphan drugs: alpha 1-antitrypsin for alpha1-antitrypsin deficiency, eliglustat for Gaucher disease and tolvaptan for autosomal dominant polycystic kidney disease.